NASDAQ:XERS

Xeris Pharmaceuticals Stock Earnings Reports

etoro logo Buy XERS
*Your capital is at risk
$7.26
+0.0800 (+1.11%)
At Close: Nov 17, 2025

Xeris Pharmaceuticals Earnings Calls

Sep 30, 2025
Release date Nov 06, 2025
EPS estimate $0.0100
EPS actual -
Revenue estimate 81.383M
Revenue actual 74.063M
Revenue Surprise -8.99%
Jun 30, 2025
-$0.0100 (66.67%)
Release date Aug 07, 2025
EPS estimate -$0.0300
EPS actual -$0.0100
EPS Surprise 66.67%
Revenue estimate 72.25M
Revenue actual 71.539M
Revenue Surprise -0.98%
Mar 31, 2025
-$0.0600 (14.29%)
Release date May 08, 2025
EPS estimate -$0.0700
EPS actual -$0.0600
EPS Surprise 14.29%
Revenue estimate 57.61M
Revenue actual 60.119M
Revenue Surprise 4.36%
Dec 31, 2024
-$0.0300 (62.50%)
Release date Mar 06, 2025
EPS estimate -$0.0800
EPS actual -$0.0300
EPS Surprise 62.50%
Revenue estimate 54.9M
Revenue actual 60.099M
Revenue Surprise 9.47%

Last 4 Quarters for Xeris Pharmaceuticals

Below you can see how XERS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Dec 31, 2024 Beat
Release date Mar 06, 2025
Price on release $4.13
EPS estimate -$0.0800
EPS actual -$0.0300
EPS surprise 62.50%
Date Price
Feb 28, 2025 $3.83
Mar 03, 2025 $3.69
Mar 04, 2025 $3.75
Mar 05, 2025 $3.77
Mar 06, 2025 $4.13
Mar 07, 2025 $4.24
Mar 10, 2025 $4.59
Mar 11, 2025 $4.39
Mar 12, 2025 $4.57
4 days before 7.83%
4 days after 10.65%
On release day 2.66%
Change in period 19.32%
Mar 31, 2025 Beat
Release date May 08, 2025
Price on release $5.16
EPS estimate -$0.0700
EPS actual -$0.0600
EPS surprise 14.29%
Date Price
May 02, 2025 $4.71
May 05, 2025 $4.64
May 06, 2025 $4.30
May 07, 2025 $4.48
May 08, 2025 $5.16
May 09, 2025 $5.01
May 12, 2025 $4.95
May 13, 2025 $4.90
May 14, 2025 $4.64
4 days before 9.55%
4 days after -10.08%
On release day -2.91%
Change in period -1.49%
Jun 30, 2025 Beat
Release date Aug 07, 2025
Price on release $6.60
EPS estimate -$0.0300
EPS actual -$0.0100
EPS surprise 66.67%
Date Price
Aug 01, 2025 $5.38
Aug 04, 2025 $5.56
Aug 05, 2025 $5.48
Aug 06, 2025 $5.49
Aug 07, 2025 $6.60
Aug 08, 2025 $6.84
Aug 11, 2025 $7.20
Aug 12, 2025 $7.30
Aug 13, 2025 $7.28
4 days before 22.68%
4 days after 10.30%
On release day 3.64%
Change in period 35.32%
Sep 30, 2025
Release date Nov 06, 2025
Price on release $7.71
EPS estimate $0.0100
EPS actual -
Date Price
Oct 31, 2025 $9.70
Nov 03, 2025 $9.90
Nov 04, 2025 $9.90
Nov 05, 2025 $9.87
Nov 06, 2025 $7.71
Nov 07, 2025 $7.43
Nov 10, 2025 $7.72
Nov 11, 2025 $7.44
Nov 12, 2025 $7.59
4 days before -20.52%
4 days after -1.56%
On release day -3.63%
Change in period -21.75%

Xeris Pharmaceuticals Earnings History

Earnings Calendar

FAQ

When is the earnings report for XERS?
Xeris Pharmaceuticals Inc (XERS) has scheduled its earnings report for Mar 05, 2026 before the markets open.

What is the XERS price-to-earnings (P/E) ratio?
XERS P/E ratio as of Nov 17, 2025 (TTM) is -35.00.

What is the XERS EPS forecast?
The forecasted EPS (Earnings Per Share) for Xeris Pharmaceuticals Inc (XERS) for the first fiscal quarter 2025 is $0.0300.

What are Xeris Pharmaceuticals Inc's retained earnings?
On its balance sheet, Xeris Pharmaceuticals Inc reported retained earnings of $74.06 million for the latest quarter ending Sep 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT XERIS PHARMACEUTICALS INC
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE